Treatment of acne in women ovarian hyperandrogenism and insulin resistance

Objective. To determine the efficacy of Glucophage, a biguanide manufactured by MERCK SANTE s.a.s) (France), in the treatment of women with acne, ovarian hyperandrogenism and insulin resistance. Materials and methods. The study involved 65 women aged 20—40, who were administered Glucophage (a biguanide) for a year. The dynamical analysis of acne components and mean values of the acne dermatology index was performed, the therapeutic effect was assessed, and the subjects underwent gynecological and anthropometric examinations as well as laboratory tests: blood hormone level; urine steroid profile; metabolic status; cholesterol, triglycerides and blood biochemistry test as well as ultrasonic examination of small pelvis organs and sebometry. Results. The treatment reduced the acne dermatology index by 89.12%; the therapeutic effect was achieved in 84.62% of the patients; the treatment also produced a positive effect on anthropometric characteristics and resulted in the normalization of the hormonal status, urine steroid profile indices as well as lipid and carbohydrate metabolism, and moderate suppression of the skin fat secretion. Conclusion. The treatment of women suffering from acne, ovarian hyperandrogenism and insulin resistance with Glucophage normalized carbohydrate metabolism, hormonal status and urine steroid profile, which resulted in a positive therapeutic effect on acne.